We are live on ! Find out more
VKTX icon

Viking Therapeutics

143 hedge funds and large institutions have $212M invested in Viking Therapeutics in 2020 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 44 increasing their positions, 50 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more call options, than puts

Call options by funds: $4.78M | Put options by funds: $2.87M

18% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 17

2% more funds holding

Funds holding: 140143 (+3)

2.64% less ownership

Funds ownership: 54.37%51.73% (-2.6%)

8% less capital invested

Capital invested by funds: $230M → $212M (-$17.6M)

12% less repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 50

Holders
143
Holders Change
+3
Holders Change %
+2.14%
% of All Funds
2.53%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
20
Increased
44
Reduced
50
Closed
17
Calls
$4.78M
Puts
$2.87M
Net Calls
+$1.91M
Net Calls Change
-$3.6M

VKTX Hedge Fund Activity: Q4 2020 in Review

143 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics (VKTX) for Q4 2020, worth a combined $212M — down 7.7% from $230M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new VKTX positions and 17 closed out — a net gain of 3 holders — while 44 added to existing stakes and 50 trimmed.

The largest buyer was BlackRock, adding an estimated $3.67M. The largest seller was Fidelity Investments, cutting an estimated $9.69M.

  • 143 institutional investors held Viking Therapeutics (VKTX) as of Q4 2020, up from 140 in Q3 2020.
  • Funds reported $212M of Viking Therapeutics stock for Q4 2020, down 7.7% quarter-over-quarter.
  • 20 funds opened new Viking Therapeutics positions in Q4 2020 and 17 closed out, a net change of +3 holders.
  • The largest Viking Therapeutics buyer in Q4 2020 was BlackRock, an estimated $3.67M added.
  • The largest Viking Therapeutics seller in Q4 2020 was Fidelity Investments, an estimated $9.69M sold.

Based on aggregated 13F filings for Q4 2020.